These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1615 related items for PubMed ID: 11118046

  • 1. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ, Grigoryev DN, Nnane IP, Liu Y, Ling YZ, Brodie AM.
    Cancer Res; 2000 Dec 01; 60(23):6630-40. PubMed ID: 11118046
    [Abstract] [Full Text] [Related]

  • 2. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
    Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman D, Farquhar R, Guo Z, Qiu Y, Brodie AM.
    J Med Chem; 2005 Apr 21; 48(8):2972-84. PubMed ID: 15828836
    [Abstract] [Full Text] [Related]

  • 3. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.
    Grigoryev DN, Long BJ, Nnane IP, Njar VC, Liu Y, Brodie AM.
    Br J Cancer; 1999 Oct 21; 81(4):622-30. PubMed ID: 10574247
    [Abstract] [Full Text] [Related]

  • 4. Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis.
    Nnane IP, Long BJ, Ling YZ, Grigoryev DN, Brodie AM.
    Br J Cancer; 2000 Jul 21; 83(1):74-82. PubMed ID: 10883671
    [Abstract] [Full Text] [Related]

  • 5. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep 21; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 6. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
    Klus GT, Nakamura J, Li JS, Ling YZ, Son C, Kemppainen JA, Wilson EM, Brodie AM.
    Cancer Res; 1996 Nov 01; 56(21):4956-64. PubMed ID: 8895750
    [Abstract] [Full Text] [Related]

  • 7. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS.
    Prostate; 2004 Feb 01; 58(2):130-44. PubMed ID: 14716738
    [Abstract] [Full Text] [Related]

  • 8. Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor.
    Grigoryev DN, Long BJ, Njar VC, Brodie AH.
    J Steroid Biochem Mol Biol; 2000 Dec 01; 75(1):1-10. PubMed ID: 11179903
    [Abstract] [Full Text] [Related]

  • 9. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S, Agoulnik IU, Weigel NL.
    Prostate; 2005 Sep 01; 64(4):362-72. PubMed ID: 15754350
    [Abstract] [Full Text] [Related]

  • 10. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N, Miyamoto H, Mizokami A, Harada S, Nomura M, Ueta Y, Sasaguri T, Matsumoto T.
    Cancer Invest; 2007 Feb 01; 25(1):32-7. PubMed ID: 17364555
    [Abstract] [Full Text] [Related]

  • 11. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Pandini G, Mineo R, Frasca F, Roberts CT, Marcelli M, Vigneri R, Belfiore A.
    Cancer Res; 2005 Mar 01; 65(5):1849-57. PubMed ID: 15753383
    [Abstract] [Full Text] [Related]

  • 12. Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3'-diindolylmethane (ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells.
    Abdelbaqi K, Lack N, Guns ET, Kotha L, Safe S, Sanderson JT.
    Prostate; 2011 Sep 15; 71(13):1401-12. PubMed ID: 21321979
    [Abstract] [Full Text] [Related]

  • 13. Antiandrogenic mechanisms of pesticides in human LNCaP prostate and H295R adrenocortical carcinoma cells.
    Robitaille CN, Rivest P, Sanderson JT.
    Toxicol Sci; 2015 Jan 15; 143(1):126-35. PubMed ID: 25324206
    [Abstract] [Full Text] [Related]

  • 14. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
    Kawata H, Arai S, Nakagawa T, Ishikura N, Nishimoto A, Yoshino H, Shiraishi T, Tachibana K, Nakamura R, Sato H.
    Prostate; 2011 Sep 15; 71(12):1344-56. PubMed ID: 21308717
    [Abstract] [Full Text] [Related]

  • 15. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T, Nakamura K, Araki H, Kusaka M, Yamaoka M.
    Cancer Res; 2003 Sep 01; 63(17):5622-8. PubMed ID: 14500404
    [Abstract] [Full Text] [Related]

  • 16. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
    Nnane IP, Kato K, Liu Y, Lu Q, Wang X, Ling YZ, Brodie A.
    Cancer Res; 1998 Sep 01; 58(17):3826-32. PubMed ID: 9731491
    [Abstract] [Full Text] [Related]

  • 17. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ.
    Cancer Res; 2004 Aug 01; 64(15):5489-95. PubMed ID: 15289359
    [Abstract] [Full Text] [Related]

  • 18. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer.
    Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, Menon M, Dou QP, Reddy GP.
    Cancer Res; 2007 Aug 15; 67(16):7782-8. PubMed ID: 17699783
    [Abstract] [Full Text] [Related]

  • 19. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
    Landriscina M, Bagalà C, Piscazzi A, Schinzari G, Quirino M, Fabiano A, Bianchetti S, Cassano A, Sica G, Barone C.
    Prostate; 2009 May 15; 69(7):744-54. PubMed ID: 19152342
    [Abstract] [Full Text] [Related]

  • 20. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.
    Cancer Res; 2004 Oct 01; 64(19):7156-68. PubMed ID: 15466214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 81.